Tiny drug-laden 'popping bubbles' lead triple attack treatment for liver cancer

December 7, 2015, University of Illinois at Urbana-Champaign
Bexarotene prodrug in nanobubble form is inserted directly into the tumor using a flexible catheter. Ultrasound ablation therapy to 'pop' the bubbles to release the agent. Credit: University of Illinois

In an interdisciplinary collaboration between prominent academic and industry investigators, researchers have discovered a novel method for repositioning an FDA-approved anti-cancer compound so it can specifically target liver cancer tumors. A 'triple attack' technique combining chemotherapy, thermal ablation, and hyperthermia provided a highly targeted, yet minimally invasive approach.

"In this study, we re-purposed the topical agent bexarotene (Targretin)—currently in limited use for cutaneous manifestations of T-cell lymphomas—and re-engineered it for use in solid tumor applications by forming self-assembling nanobubbles," explained Dipanjan Pan, assistant professor of bioengineering at the University of Illinois at Urbana-Champaign, who led the study. "These tiny bubbles filled with Targretin in 'prodrug' form can be 'popped' to release the drug inside cells, activating the prodrug during cellular internalization process. The probability of its undesired systemic release is minimal due to this highly selective activation mechanism, which helps to spare the healthy cells."

The American Cancer Society estimated that by the end of this year, approximately 1.66 million new cancer cases will be diagnosed in the United States, and the figure goes up once the global statistics is taken into consideration. Developing new cancer-treatment drugs through a conventional drug discovery pipeline is time-consuming and expensive. One solution is to re-purpose a drug that is already approved for human use to treat a disease can be re-examined for treating other diseases.

"Liver cancer is normally difficult to attack and usually requires significant surgical intervention," stated Santosh Misra, a postdoctoral research associate in Pan's laboratory and first author of the paper, "Trimodal Therapy: Combining Hyperthermia with Re-purposed Bexarotene and Ultrasound for Treating Liver Cancer," published in ACS Nano, the premier nanotechnology journal of the American Chemical Society. "In this study, we successfully re-purposed and repackaged bexarotene into a sensitive nanobubble form, inserted it directly into the tumor using a flexible catheter, and used ultrasound ablation therapy to 'pop' the bubbles to release the agent."

The university researchers teamed up with a biomedical company Acoustic MedSystem to apply a newly designed catheter-based ultrasound therapeutic device with spatially tracked 3D ultrasound imaging.

"Using an in vitro model of hepatocellular carcinoma and an in vivo large animal model of liver ablation, we demonstrated the effectiveness of bexarotene prodrug nanobubbles when used in conjunction with catheter-based ultrasound, thereby highlighting the therapeutic promise of this trimodal approach," Pan added. "Using a swine cancer model for drug screening is rare, providing us a great opportunity to study this new class of therapeutic nanobubble in a preclinical system closer to human. Furthermore, the study uniquely looks at the system from atomic to molecular to cell, tissue and then organ level. With this result in hand, the next step could be to test them in humans!"

Explore further: Guided ultrasound plus nanoparticle chemotherapy cures tumors in mice

More information: Santosh K. Misra et al. Trimodal Therapy: Combining Hyperthermia with Repurposed Bexarotene and Ultrasound for Treating Liver Cancer, ACS Nano (2015). DOI: 10.1021/acsnano.5b05974

Related Stories

Shrinking tumors with an RNA triple-helix hydrogel glue

December 7, 2015

Twenty years ago, scientists discovered that short strands of RNA known as microRNA help cells to fine-tune their gene expression. Disruption or loss of some microRNAs has been linked to cancer, raising the possibility of ...

Portrazza approved for advanced lung cancer

November 25, 2015

(HealthDay)—Portrazza (necitumumab), in combination with two other chemotherapy drugs, has been approved by the U.S. Food and Drug Administration to treat advanced squamous non-small cell lung cancer, the agency said Tuesday ...

Recommended for you

Paleontologists report world's biggest Tyrannosaurus rex

March 22, 2019

University of Alberta paleontologists have just reported the world's biggest Tyrannosaurus rex and the largest dinosaur skeleton ever found in Canada. The 13-metre-long T. rex, nicknamed "Scotty," lived in prehistoric Saskatchewan ...

NASA instruments image fireball over Bering Sea

March 22, 2019

On Dec. 18, 2018, a large "fireball—the term used for exceptionally bright meteors that are visible over a wide area—exploded about 16 miles (26 kilometers) above the Bering Sea. The explosion unleashed an estimated 173 ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.